Structured Abstract

Contents

• Key Messages
• PREFACE
• Acknowledgements
• Technical Expert Panel
• Peer Reviewers
• Evidence Summary
  • Background
  • Key Questions
  • Methods
  • Results
  • Discussion
  • Future Research Needs
  • Conclusion
  • References
• Introduction
  • Background
  • Key Questions
• Methods
  • Protocol
  • Search Strategy
  • Study Selection
  • Risk of Bias Assessment
  • Data Synthesis
  • Strength of the Body of Evidence
  • Applicability
• Results
  • Results of the Literature Search
  • Key Question 1. What is the evidence for the efficacy of subcutaneous immunotherapy (SCIT) in the treatment of asthma?
  • Key Question 2. What is the evidence for the safety of subcutaneous immunotherapy (SCIT) in the treatment of asthma?
  • Key Question 3. What is the evidence for the efficacy of sublingual immunotherapy (SLIT), in tablet and aqueous form, for the treatment of asthma?
  • Key Question 4. What is the evidence for the safety of sublingual immunotherapy (SLIT) in the treatment of asthma?
  • Subcutaneous Versus Sublingual Immunotherapy
• Discussion
  • Limitations
  • Applicability
• Future Research Needs
  • Population
  • Intervention and Comparison
  • Outcomes
  • Conclusion
• References
• Appendix A. Detailed Electronic Database Search Strategies
• Appendix B. Glossary and List of Definitions
• Appendix C. List of Excluded Articles
• Appendix D. KQ1- What is the evidence for the efficacy of subcutaneous immunotherapy (SCIT) in the treatment of asthma?
• Appendix E. KQ2- What is the evidence for the safety of subcutaneous immunotherapy (SCIT) in the treatment of asthma?
• Appendix F. KQ3- What is the evidence for the efficacy of sublingual immunotherapy (SLIT) in tablet and aqueous form, in the treatment of asthma?
• Appendix G. KQ4- What is the evidence for the safety of sublingual immunotherapy (SLIT) in tablet and aqueous form, in the treatment of asthma?
• Appendix H. Sublingual Versus Subcutaneous Immunotherapy
• Appendix I. Risk of Bias Assessment
• Appendix J. References

Suggested citation:

Lin SY, Azar A, Suarez-Cuervo C, Diette GB, Brigham E, Rice J, Ramanathan M, Gayleard J, Robinson KA. The Role of Immunotherapy in the Treatment of Asthma. Comparative Effectiveness Review No. 196 (Prepared by the Johns Hopkins University Evidence-based Practice Center under Contract No.290-2015-00006-I). AHRQ Publication No. 17(18)-EHC029-EF. Rockville, MD: Agency for Healthcare Research and Quality. March 2018. Posted final reports are located on the Effective Health Care Program search page. DOI: https://doi.org/10.23970/AHRQEPCCER196.

This report is based on research conducted by the Johns Hopkins University EPC under contract to the Agency for Healthcare Research and Quality (AHRQ), Rockville, MD (Contract No. 290-2015-00006-I). The findings and conclusions in this document are those of the authors, who are responsible for its contents; the findings and conclusions do not necessarily represent the views of AHRQ. Therefore, no statement in this report should be construed as an official position of AHRQ or of the U.S. Department of Health and Human Services.

None of the investigators have any affiliations or financial involvement that conflicts with the material presented in this report.

The information in this report is intended to help health care decisionmakers—patients and clinicians and health system leaders, among others—make well-informed decisions and thereby improve the quality of health care services. This report is not intended to be a substitute for the application of clinical judgment. Anyone who makes decisions concerning the provision of clinical care should consider this report in the same way as any medical reference and in conjunction with all other pertinent information (i.e., in the context of available resources and circumstances presented by individual patients).

This report is made available to the public under the terms of a licensing agreement between the author and the Agency for Healthcare Research and Quality. This report may be used and reprinted without permission except those copyrighted materials that are clearly noted in the report. Further reproduction of those copyrighted materials is prohibited without the express permission of copyright holders.

AHRQ or U.S. Department of Health and Human Services endorsement of any derivative products that may be developed from this report, such as clinical practice guidelines, other quality-enhancement tools, or reimbursement or coverage policies may not be stated or implied.

This report may periodically be assessed for the currency of conclusions. If an assessment is done, the resulting surveillance report describing the methodology and findings will be found on the Effective Health Care Program Web site at: www.effectivehealthcare.ahrq.gov. Search on the title of the report.

Persons using assistive technology may not be able to fully access information in this report. For assistance contact vog.shh.qrha@eraChtlaeHevitceffE.

1

5600 Fishers Lane, Rockville, MD 20857; http://www​.ahrq.gov